Search
New Jersey Paid Clinical Trials
A listing of 1772 clinical trials in New Jersey actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
49 - 60 of 1772
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Recruiting
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Atlantic Health, Morristown, New Jersey
Conditions: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Recruiting
The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumors
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
Recruiting
This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to cCRT followed by durvalumab with respect to the following... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Rutgers Cancer Institute of New Jersey ( Site 2805), New Brunswick, New Jersey
Conditions: Carcinoma, Non-Small-Cell Lung
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Recruiting
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Englewood Hospital and Medical Center ( Site 3557), Englewood, New Jersey
Conditions: Carcinoma, Renal Cell
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Recruiting
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
DLBCL is also a type of cancer of the blood. They are referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. The study has 2 main parts, called phase 1 and phase 1b. The main objective of both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Astera Cancer Care, East Brunswick, New Jersey
Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001)
Recruiting
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey
Conditions: Advanced Solid Tumors
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Recruiting
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
Gender:
All
Ages:
1 year and above
Trial Updated:
11/30/2023
Locations: Clinical Trial Site, New Brunswick, New Jersey
Conditions: Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Recruiting
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499... Read More
Gender:
All
Ages:
All
Trial Updated:
11/30/2023
Locations: Novo Nordisk Investigational Site, Florham Park, New Jersey
Conditions: Non-alcoholic Steatohepatitis
Stroke Thrombectomy and Aneurysm Registry
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
All
Ages:
Between 1 year and 120 years
Trial Updated:
11/30/2023
Locations: Rutgers University, New Brunswick, New Jersey
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
Recruiting
This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.
Gender:
All
Ages:
Between 6 years and 55 years
Trial Updated:
11/30/2023
Locations: Novartis Investigative Site, Ocean City, New Jersey
Conditions: Allergy, Peanut
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Local Institution - 015, Summit, New Jersey
Conditions: Multiple Myeloma
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumors